A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab Vedotin

Trial Profile

A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab Vedotin

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
  • Indications Lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Dec 2017 Results (n=8) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 02 Nov 2017 New drug Nivolumab has been added in the study. Hence treatment arms has been changed from 1 to 2.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top